# Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial

> **NCT04518774** · EARLY_PHASE1 · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 8 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Ex-vivo expanded allogeneic γδT cells

## Key facts

- **NCT ID:** NCT04518774
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-15
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-08-15
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2020-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04518774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04518774, "Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04518774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*